The Valley Desk

ArticleOncotargetPublished

Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers and overcomes cancer stemness, trifluridine-induced angiogenesis, ERK1/2 and STAT3 signaling regardless of KRAS or BRAF mutational status

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Article
Venue
Oncotarget
Published
Subject terms
Cell Line, Tumor; Animals; Humans; Mice; Gastrointestinal Neoplasms; Neovascularization, Pathologic; Phenylurea Compounds; Pyridines; Uracil; Thymine; Pyrrolidines; Proto-Oncogene Proteins B-raf
PubMed ID
38953895
PubMed Central ID
PMC11218792
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal